Respiratory Function Changes After Asbestos Pleurisy
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Occupational Airborne Particulates
Environmental Burden of Disease Series, No. 7 Occupational airborne particulates Assessing the environmental burden of disease at national and local levels Tim Driscoll Kyle Steenland Deborah Imel Nelson James Leigh Series Editors Annette Prüss-Üstün, Diarmid Campbell-Lendrum, Carlos Corvalán, Alistair Woodward World Health Organization Protection of the Human Environment Geneva 2004 WHO Library Cataloguing-in-Publication Data Occupational airborne particulates : assessing the environmental burden of disease at national and local levels / Tim Driscoll … [et al.]. (Environmental burden of disease series / series editors: Annette Prüss-Ustun ... [et al.] ; no. 7) 1.Dust - adverse effects 2.Occupational exposure 3.Asthma - chemically induced 4.Pulmonary disease, Chronic obstructive - chemically induced 5.Pneumoconiosis - etiology 6.Cost of illness 7.Epidemiologic studies 8.Risk assessment - methods 9.Manuals I.Driscoll, Tim. II.Prüss-Üstün, Annette. III.Series. ISBN 92 4 159186 2 (NLM classification: WA 450) ISSN 1728-1652 Suggested Citation Tim Driscoll, et al. Occupational airborne particulates: assessing the environmental burden of disease at national and local levels. Geneva, World Health Organization, 2004. (Environmental Burden of Disease Series, No. 7). © World Health Organization 2004 All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: [email protected]). -
PICTORIAL REVIEW Thoracic Involvement in Connective
JBR–BTR, 2015, 98: 3-19. PICTORIAL REVIEW THORACIC INVOLVEMENT IN CONNECTIVE TISSUE DISEASES: RADIO- LOGICAL PATTERNS AND FOLLOW-UP G. Serra1, A.-L. Brun1, P. Ialongo2, M.-L. Chabi1, P.A. Grenier1 Connective tissue diseases (CTDs) are a heterogeneous group of idiopathic inflammatory diseases involving various organs. A thoracic involvement is frequent, and chest-CT represents the imaging technique of reference in its assess- ment. Pulmonary abnormalities related to CTDs are various; although several disease-specific aspects have been described, the two most clinically relevant complications are represented by interstitial lung disease and pulmonary arterial hypertension. The early identification of a thoracic involvement, with the adoption of specific therapies, can significantly change patient’s prognosis. The aim of this article is to review the most common typical and atypical CT features of thoracic involvement occurring in CT, especially focusing on interstitial lung disease. Key-word: Connective tissue, diseases – Lung, interstitial disease – Hypertension, pulmonary. Connective tissue diseases (CTDs) at the time of diagnosis of CTD, or chronic inflammation in the alveolar are a heterogeneous group of in- more commonly manifest later in the walls. The patients usually response flammatory diseases derived from course of the disease (5, 6). well to corticosteroid therapy and an immunologic deregulation affect- The most common histopatholog- have a good prognosis. However pa- ing various organs. A thoracic in- ic patterns of ILD seen in the setting tients with OP associated with CTD volvement (pulmonary, pleural or of CTDs are non specific interstitial seem to have a greater tendency to mediastinal) can be frequently pneumonia (NSIP), usual interstitial develop fibrosis and a higher mortal- found; its frequency and expression pneumonia (UIP), organizing pneu- ity than patients with cryptogenic depends on the type of disease, and monia (OP), diffuse alveolar damage OP (5, 6). -
Management of Malignant Pleural Effusions an Official ATS/STS/STR Clinical Practice Guideline David J
AMERICAN THORACIC SOCIETY DOCUMENTS Management of Malignant Pleural Effusions An Official ATS/STS/STR Clinical Practice Guideline David J. Feller-Kopman*, Chakravarthy B. Reddy*, Malcolm M. DeCamp, Rebecca L. Diekemper, Michael K. Gould, Travis Henry, Narayan P. Iyer, Y. C. Gary Lee, Sandra Z. Lewis, Nick A. Maskell, Najib M. Rahman, Daniel H. Sterman, Momen M. Wahidi, and Alex A. Balekian; on behalf of the American Thoracic Society, Society of Thoracic Surgeons, and Society of Thoracic Radiology THIS OFFICIAL CLINICAL PRACTICE GUIDELINE WAS APPROVED BY THE AMERICAN THORACIC SOCIETY OCTOBER 2018, THE SOCIETY OF THORACIC SURGEONS JUNE 2018, AND THE SOCIETY OF THORACIC RADIOLOGY JULY 2018 Background: This Guideline, a collaborative effort from the MPE; 3) using either an indwelling pleural catheter (IPC) or American Thoracic Society, Society of Thoracic Surgeons, and chemical pleurodesis in symptomatic patients with MPE and Society of Thoracic Radiology, aims to provide evidence-based suspected expandable lung; 4) performing large-volume recommendations to guide contemporary management of patients thoracentesis to assess symptomatic response and lung expansion; with a malignant pleural effusion (MPE). 5) using either talc poudrage or talc slurry for chemical pleurodesis; 6) using IPC instead of chemical pleurodesis in patients with Methods: A multidisciplinary panel developed seven questions nonexpandable lung or failed pleurodesis; and 7) treating using the PICO (Population, Intervention, Comparator, and IPC-associated infections with antibiotics and not removing the Outcomes) format. The GRADE (Grading of Recommendations, catheter. Assessment, Development and Evaluation) approach and the Evidence to Decision framework was applied to each question. Recommendations Conclusions: These recommendations, based on the best available were formulated, discussed, and approved by the entire panel. -
Pneumoconiosis
Prim Care Respir J 2013; 22(2): 249-252 PERSPECTIVE Pneumoconiosis *Paul Cullinan1, Peter Reid2 1 Consultant Physician, Royal Brompton and Harefield NHS Foundation Trust, London, UK 2 Consultant Physician, Western General Hospital, Edinburgh, UK Introduction Figure 1. Asbestosis; the HRCT scan shows the typical The pneumoconioses are parenchymal lung diseases that arise from picture of subpleural fibrosis (solid arrow); in addition inhalation of (usually) inorganic dusts at work. Some such dusts are there is diffuse, left-sided pleural thickening (broken biologically inert but visible on a chest X-ray or CT scan; thus, while arrow), characteristic too of heavy asbestos exposure they are radiologically alarming they do not give rise to either clinical disease or deficits in pulmonary function. Others – notably asbestos and crystalline silica – are fibrogenic so that the damage they cause is through the fibrosis induced by the inhaled dust rather than the dust itself. Classically these give rise to characteristic radiological patterns and restrictive deficits in lung function with reductions in diffusion capacity; importantly, they may progress long after exposure to the causative mineral has finished. In the UK and similar countries asbestosis is the commonest form of pneumoconiosis but in less developed parts of the world asbestosis is less frequent than silicosis; these two types are discussed in detail below. Other, rarer types of pneumoconiosis include stannosis (from tin fume), siderosis (iron), berylliosis (beryllium), hard metal disease (cobalt) and coal worker’s pneumoconiosis. Asbestosis Clinical scenario How is the diagnosis made? Asbestosis is the ‘pneumoconiosis’ that arises from exposure to A man of 78 reports gradually worsening breathlessness; he has asbestos in the workplace.1 The diagnosis is made when, on the no relevant medical history of note and has never been a regular background of heavy occupational exposure to any type of asbestos, smoker. -
Occupational Lung Diseases
24 Occupational lung diseases Introduction i Occupational diseases are often thought to be Key points uniquely and specifically related to factors in the work environment; examples of such diseases are • Systematic under-reporting and the pneumoconioses. However, in addition to other difficulties in attributing causation both contribute to underappreciation of the factors (usually related to lifestyle), occupational burden of occupational respiratory exposures also contribute to the development or diseases. worsening of common respiratory diseases, such • Work-related exposures are estimated as chronic obstructive pulmonary disease (COPD), to account for about 15% of all adult asthma and lung cancer. asthma cases. • Boththe accumulation of toxic dust in the Information about the occurrence of occupational lungs and immunological sensitisation respiratory diseases and their contribution to to inhaled occupational agents can morbidity and mortality in the general population is cause interstitial lung disease. provided by different sources of varying quality. Some • Despite asbestos use being phased European countries do not register occupational out, mesothelioma rates are forecast diseases and in these countries, information about to continue rising owing to the long latency of the disease. the burden of such diseases is completely absent. • The emergence of novel occupational In others, registration is limited to cases where causes of respiratory disease in compensation is awarded, which have to fulfil specific recent years emphasises the need for administrative or legal criteria as well as strict continuing vigilance. medical criteria; this leads to biased information and underestimation of the real prevalence. Under- reporting of occupational disease is most likely to occur in older patients who are no longer at work but whose condition may well be due to their previous job. -
Pathological Aspects of Asbestosis
POSTGRAD. MED. J. (1966), 42, 613. Postgrad Med J: first published as 10.1136/pgmj.42.492.613 on 1 October 1966. Downloaded from PATHOLOGICAL ASPECTS OF ASBESTOSIS D. O'B. HOURIHANE, M.D., M.C.Path., D.C.P.(Lond.), M.R.C.P.I. W. T. E. MCCAUGHEY, M.D., M.C.Path. School ofPathology, Trinity College, Dublin WIDESPREAD recognition of asbestosis dates from the work of Merewether and Price in 1930. They investigated 363 asbestos workers and concluded that there was a pneumoconiosis resulting from asbestos inhalation, that this condition shortened life, and that measures to diminish the atmospheric concentration of asbestos dust would reduce the incidence of the disease. In 1931 asbestosis was accepted as a compensatable disease in Great Britain and steps were taken to reduce the risk in the asbestos industry. 18 years later Wyers (1949) found that the age at death in this disorder had Protected by copyright. increased and that finger-clubbing had become more common. He suggested that these changes were due to a more chronic form of the disease resulting from improved dust control in the industry following the legislation of 1931. Currently however, the number of new cases of asbestosis in Great Britain is increasing, their frequency suggesting an incidence rate of at least five per thousand of those occupation- ally exposed (McVittie, 1965). Though earlier reports indicated that tuberculosis was common in asbestosis (Wyers, 1949; Gloyne, 1951; Bonser, Foulds and Stewart, 1955) it appears to be a rare I 0 n < ,. ' complication at the present time (Buchanan, 1965). -
08-0205: N.M. and DEPARTMENT of the NAVY, PUGET S
United States Department of Labor Employees’ Compensation Appeals Board __________________________________________ ) N.M., Appellant ) ) and ) Docket No. 08-205 ) Issued: September 2, 2008 DEPARTMENT OF THE NAVY, PUGET ) SOUND NAVAL SHIPYARD, Bremerton, WA, ) Employer ) __________________________________________ ) Appearances: Oral Argument July 16, 2008 John Eiler Goodwin, Esq., for the appellant No appearance, for the Director DECISION AND ORDER Before: DAVID S. GERSON, Judge COLLEEN DUFFY KIKO, Judge JAMES A. HAYNES, Alternate Judge JURISDICTION On October 30, 2007 appellant filed a timely appeal from a November 17, 2006 decision of the Office of Workers’ Compensation Programs denying his occupational disease claim. Pursuant to 20 C.F.R. §§ 501.2(c) and 501.3, the Board has jurisdiction over the merits of the claim. ISSUE The issue is whether appellant has established that he sustained occupational asthma in the performance of duty due to accepted workplace exposures. On appeal, he, through his attorney, asserts that the Office did not provide Dr. William C. Stewart, the impartial medical examiner, with a complete, accurate statement of accepted facts. FACTUAL HISTORY On December 8, 2004 appellant, then a 57-year-old insulator, filed an occupational disease claim (Form CA-2) asserting that he sustained occupational asthma and increasing shortness of breath due to workplace exposures to fiberglass, silicates, welding smoke, polychlorobenzenes, rubber, dusts, gases, fumes and smoke from “burning out” submarines from 1991 through January -
Cryptococcus Pneumonia Presenting in an Immunocompetent Host with Pulmonary Asbestosis
Guy et al. Journal of Medical Case Reports 2012, 6:170 JOURNAL OF MEDICAL http://www.jmedicalcasereports.com/content/6/1/170 CASE REPORTS CASE REPORT Open Access Cryptococcus pneumonia presenting in an immunocompetent host with pulmonary asbestosis: a case report Judah P Guy1, Shahzad Raza1,2*, Elliot Bondi1, Yale Rosen2, Dong-Sung Kim2 and Barbara J Berger1 Abstract Introduction: Cryptococcal infections pose a diagnostic challenge in an immunocompetent host. Asbestos exposure has been associated with pulmonary aspergillosis. This case highlights an interesting presentation of cryptococcal lung inflammation with underlying asbestosis. Case presentation: A 63-year-old Mediterranean Caucasian woman presented with progressive dry cough of nine months duration. A computed tomography (CT) scan of her chest revealed multiple foci in the right infra-hilar region, which were seen as hot lung masses on a positron emission tomography (PET) scan. These multiple foci appeared metastatic in nature throughout both lung fields with early mediastinal invasion. A computed tomography (CT)-guided core biopsy was obtained from a dominant right lower lobe lung mass. Histology showed chronic granulomatous inflammation with numerous budding yeast forms that were GMS-, PAS-, and mucin- positive, consistent with cryptococcosis together with asbestos bodies (ferruginous). She was managed with fluconazole (400mg (6mg/kg) per day orally) daily. At her six-month follow up, she had marked improvement in her general condition along with a diminution of the lower lobe lung mass. Conclusion: We report a clinical and radiological improvement in a patient treated for cryptococcal pneumonia. Asbestos exposure was likely to have been an important pathophysiological precursor to infection by environmental fungi. -
Living with Asbestos-Related Illness a Self-Care Guide
Living With Asbestos-Related Illness A Self-Care Guide For more information, contact ATSDR’s toll-free information line: (888) 42-ATSDR. that’s (888) 422-8737 ATSDR’s Internet address is www.atsdr.cdc.gov 02-0024.pm What Is Asbestos? References Agency for Toxic Substances and Disease Registry. (2000); Asbestos and your health [fact sheet]. Asbestos is a rare, naturally occurring mineral with a chainlike crystal structure. Asbestos deposits Atlanta: US Department of Health and Human Services. can be found throughout the world. Deposits are still mined in Australia, Canada, South Africa, and the former Soviet Union. Asbestos is usually found mixed into other minerals. Asbestos is dangerous American Lung Association. 2000. Asbestosis. New York: American Lung Association. Available from only if its broken crystal fibers float in the air after being disturbed. URL: www.cheshire-med.com/programs/pulrehab/asbestosis.html Over the years, asbestos has had many uses. Pipe insulation, automotive brakes, shingles, wall Bartholomew D, Gainey A, Louie W, Phillips C, Sonnek N. 1999. Asbestosis. Omaha (NE): Creighton board, and blown-in insulation are just a few of the products that once contained asbestos. Although University School of Medicine. Available from URL: www.medicine.creighton.edu/forpatients/Asbes- the federal government suspended production of most asbestos products in the early 1970s, instal tosis/Asbestosis.html lation of these products continued through the late 1970s and even into the early 1980s. Asbestos fibers can be released during renovations of older buildings. Children’s Hospital of Eastern Ontario. 1999. Assisted airway clearance for Immotile Cilia syndrome. Ottawa, Ontario, Canada: Children’s Hospital of Eastern Ontario. -
Thoracic Ultrasound in the Diagnosis of Malignant Pleural Effusion
Pleural disease Thoracic ultrasound in the diagnosis of malignant Thorax: first published as 10.1136/thx.2008.100545 on 13 October 2008. Downloaded from pleural effusion N R Qureshi,1 N M Rahman,2 F V Gleeson3 See Editorial, p 97 ABSTRACT criteria established in previous studies.12 13 CECT is Background: Malignant pleural effusion (MPE) is a c Additional details of the recommended as the next investigation, with a techniques, statistical analysis common clinical problem with described investigation view to subsequent histological diagnosis (blind, and figures are published online pathways. While thoracic ultrasound (TUS) has been image-guided or thoracoscopic pleural biopsy).414 only at http://thorax.bmj.com/ shown to be accurate in pleural fluid detection, its use in Thoracic ultrasound (TUS) is a valuable clinical content/vol64/issue2 the diagnosis of malignant pleural disease has not been tool which is increasingly being performed by chest 1 Department of Radiology, assessed. A study was undertaken to assess the physicians. In the UK, guidelines have recently Papworth Hospital NHS diagnostic accuracy of TUS in differentiating malignant been published with suggested training for physi- Foundation Trust, Papworth 15 Everard, Cambridge, UK; and benign pleural disease. cians with an interest in practising TUS. 2 Oxford Centre for Respiratory Methods: 52 consecutive patients with suspected MPE Hitherto, the role of TUS has been limited to Medicine and University of underwent TUS and contrast-enhanced CT (CECT). TUS pleural fluid detection (with high sensitivity) and Oxford, Oxford Radcliffe was used to assess pleural surfaces using previously image-guided techniques (thoracocentesis, drain Hospital, Oxford, UK; placement, lung biopsy).14 3 Department of Radiology, published CT imaging criteria for malignancy, diaphrag- Oxford Radcliffe Hospital, matic thickness/nodularity, effusion size/nature and The sonographic appearance of malignant Oxford, UK presence of hepatic metastasis (in right-sided effusions). -
Asbestos Related Diseases
Asbestos Related Diseases RAFIZA SHAHARUDIN NUR NABILA ABD RAHIM INSTITUTE FOR MEDICAL RESEARCH Outline • Definition of asbestos related diseases (ARD) • Disability-Adjusted Life Year (DALY) definition • Diseases related to asbestos • ARD: Asbestosis • ARD: Asbestos related Pleural abnormality • ARD: Mesothelioma • ARD: Lung cancer • National Census/statistics (National Cancer Registry) • Asbestos related health and economic studies in Malaysia ROUTE OF EXPOSURE & BIOLOGIC FATE Exposure Biologic Fate Route Inhalation Gets lodged in lung tissue Some move to pleural or peritoneal spaces or mesothelium Ingestion Most pass through unchanged; cleared in faeces Some stay in peritoneal cavity Others enter bloodstream and into kidneys; some eliminated unchanged in urine Dermal Could get lodged in skin; may form callus or corn RISK OF ILLNESS • Depends on: • Amount & type of fibers breathed in • Duration & frequency of exposure • Other risk factors (smoking and co-morbidity) • Risk continues even after no longer exposed • Symptoms may manifest years after exposure • Not everyone exposed will develop health problem TYPE OF FIBER TYPE OF INDUSTRY AGE SMOKING STATUS HEALTH STATUS WHAT IS THE BURDEN OF DISEASE? • According to WHO, globally about 125 million people are still exposed to asbestos at the workplace. • Approximately half of deaths from occupational cancer are estimated to be caused by asbestos. • Estimated several thousand deaths annually can be attributed to exposure to asbestos in the home. • In 2004, asbestos-related diseases such as lung cancer, mesothelioma and asbestosis from occupational exposures resulted in 107,000 deaths and 1,523,000 Disability Adjusted Life Years (DALYs) (Prüss-Ustün et al, 2011) ASBESTOS RELATED DISEASES • Diseases caused by exposure to asbestos. -
Pulmonary and Tracheobronchial Amyloidosis
Pulmonary and Tracheobronchial Amyloidosis John L. Berk, M.D.,1,2,3 Anthony O’Regan, M.D.,1,3 and Martha Skinner, M.D.2,3 ABSTRACT Amyloidosis is a collection of diseases in which different proteins are deposited as insoluble -pleated sheets, disrupting organ function. Each precursor protein induces a separate spectrum of organ involvement, and different disease manifestations within the lung. Although autopsy data often demonstrate amyloid deposits in various compart- ments of the lung, few of the pathologic findings are expressed clinically. We review the pulmonary pathology, radiology, clinical presentations, and treatment options for each of the major systemic and localized forms of amyloidosis. This review focuses on amyloid derived from immunoglobulin light-chain protein (AL disease), which most frequently involves the lung in both systemic and localized forms of the disease. Manifestations of AL-related lung disease range from nodules identified on incidental chest films to diffuse alveolar+–septal deposition mimicking diffuse alveolar damage. We discuss respiratory failure due to diaphragm invasion, proximal tracheal disease, and diffuse alveolar–septal deposition. Guidelines for evaluation of patients with amyloid are presented. KEYWORDS: Amyloidosis, tracheobronchial amyloidosis, lung diseases Objectives: Upon completion of this article, the reader will understand the importance of amyloid fiber type on the spectrum of pul- monary manifestations and the natural course of disease in patients with systemic amyloidosis. Accreditation: The University of Michigan is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. Credits: The University of Michigan designates this educational activity for a maximum of 1.0 hour in category one credits toward the AMA Physicians Recognition Award.